We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

216 hedge funds and large institutions have $2.46B invested in Revance Therapeutics, Inc. in 2023 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 63 increasing their positions, 74 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more call options, than puts

Call options by funds: $57.2M | Put options by funds: $22.6M

100% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 25

81% more capital invested

Capital invested by funds: $1.36B → $2.46B (+$1.1B)

12% more funds holding

Funds holding: 193 → 216 (+23)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

15% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 74

Holders
216
Holders Change
+23
Holders Change %
+11.92%
% of All Funds
3.44%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
50
Increased
63
Reduced
74
Closed
25
Calls
$57.2M
Puts
$22.6M
Net Calls
+$34.5M
Net Calls Change
-$63.9M

Top Buyers

Rank Fund Capital Flow
1
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
+$60.7M
2
AllianceBernstein
AllianceBernstein
Tennessee
+$59M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$29.7M
4
Capital World Investors
Capital World Investors
California
+$18.6M
5
Victory Capital Management
Victory Capital Management
Texas
+$17.7M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$29.1M
2
PCH
Polar Capital Holdings
United Kingdom
-$21.2M
3
PA
Perceptive Advisors
New York
-$13.5M
4
Jennison Associates
Jennison Associates
New York
-$12.2M
5
Millennium Management
Millennium Management
New York
-$12M
Name Holding Trade Value Shares
Change 		Change in
Stake
IBT
51
International Biotechnology Trust
United Kingdom
$5.89M +$1.96M +63,000 +53%
Swiss National Bank
52
Swiss National Bank
Switzerland
$5.72M -$570K -18,300 -9%
CSS
53
Cubist Systematic Strategies
Connecticut
$5.59M -$3.4M -109,141 -39%
Canada Pension Plan Investment Board
54
Canada Pension Plan Investment Board
Ontario, Canada
$5.4M +$5.22M +167,568 New
Voloridge Investment Management
55
Voloridge Investment Management
Florida
$5.32M -$2.94M -94,427 -36%
Norges Bank
56
Norges Bank
Norway
$5.19M – – –
CS
57
Credit Suisse
Switzerland
$4.47M +$276K +8,841 +7%
Connor, Clark & Lunn Investment Management (CC&L)
58
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$4.23M +$4.1M +131,452 New
UBS Group
59
UBS Group
Switzerland
$4.23M +$1.82M +58,464 +80%
PMAM
60
Picton Mahoney Asset Management
Ontario, Canada
$4.17M +$916K +29,375 +29%
Millennium Management
61
Millennium Management
New York
$3.63M -$12M -385,262 -77%
EIM
62
Essex Investment Management
Massachusetts
$3.5M +$1.27M +40,680 +60%
RhumbLine Advisers
63
RhumbLine Advisers
Massachusetts
$3.43M +$123K +3,961 +4%
EAM
64
EULAV Asset Management
Florida
$3.38M -$2.03M -65,000 -38%
CM
65
Castleark Management
Illinois
$3.3M +$1.38M +44,220 +76%
California State Teachers Retirement System (CalSTRS)
66
California State Teachers Retirement System (CalSTRS)
California
$3.3M -$13.5K -432 -0.4%
TC
67
TwinBeech Capital
New York
$3.18M -$2.14M -68,798 -41%
WCA
68
Waypoint Capital Advisors
Minnesota
$2.93M +$1.15M +37,000 +69%
UBS AM
69
UBS AM
Illinois
$2.93M +$372K +11,928 +15%
Squarepoint
70
Squarepoint
New York
$2.87M +$98.8K +3,168 +4%
Lazard Asset Management
71
Lazard Asset Management
New York
$2.77M +$2.69M +86,155 New
DekaBank Deutsche Girozentrale
72
DekaBank Deutsche Girozentrale
Germany
$2.66M – – –
EI
73
EAM Investors
California
$2.57M +$2.49M +79,905 New
State of Wisconsin Investment Board
74
State of Wisconsin Investment Board
Wisconsin
$2.36M -$252K -8,098 -10%
State of New Jersey Common Pension Fund D
75
State of New Jersey Common Pension Fund D
New Jersey
$2.26M -$997K -31,987 -31%
1 2
3
4 5

RVNC Hedge Fund Activity: Q1 2023 in Review

216 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2023, worth a combined $2.46B — up 81% from $1.36B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new RVNC positions and 25 closed out — a net gain of 25 holders — while 63 added to existing stakes and 74 trimmed.

The largest buyer was Thrivent Financial for Lutherans, adding an estimated $60.7M. The largest seller was BlackRock, cutting an estimated $29.1M.

  • 216 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2023, up from 193 in Q4 2022.
  • Funds reported $2.46B of Revance Therapeutics, Inc. stock for Q1 2023, up 81% quarter-over-quarter.
  • 50 funds opened new Revance Therapeutics, Inc. positions in Q1 2023 and 25 closed out, a net change of +25 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q1 2023 was Thrivent Financial for Lutherans, an estimated $60.7M added.
  • The largest Revance Therapeutics, Inc. seller in Q1 2023 was BlackRock, an estimated $29.1M sold.

Based on aggregated 13F filings for Q1 2023.